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THE effect of hydrocortisone on the production of inter-
leukin-6 (IL-6) in human peripheral blood mononuclear
cells was studied. Using our newly developed radio-
immunoassay system for IL-6 of which specificity, repro-
ducibility, sensitivity and usefulness have been demon-
strated. IL-6 production in peripheral blood mononuclear
cells of ten normal subjects revealed that in lipopoly-
saccharide (LPS, 10/g/ml)-stimulation, the mean 4-SD
of IL-6 was 2.71 4- 0.85 ng/ml. No detectable amount of
IL-6 was observed in the absence of LPS and in
the presence of hydrocortisone alone. Hydrocortisone
(10-1M to 10
-3 M) inhibited LPS-stimulated IL-6 pro-
duction in a dose-dependent manner. However, there was
a wide variation in the response to hydrocortisone, namely,
ranging from steroid-sensitive to steroid-resistant. Based
on the concentration required to inhibit 50% of LPS-
stimulated IL.-6 production, three of ten subjects were at
10
-6 M, three at 10-SM and the rest at 10-4 M, respec-
tively. The dramatic anti-inflammatory and immunosup-
pressive effects of glucocorticosteroids can be life-saving
in autoimmune diseases. The present findings suggested
that there existed the differences in susceptibility to gluco-
corticosteroids even among normal subjects, providing
some implications for the drug treatment, and also gave
further evidence that there may exist an immunoregulatory
feedback circuit between the immune and neuroendocrine
systems.
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Introduction
Glucocorticoids have assumed a major role in the
treatment of numerous autoimmune, allergic and
malignant diseases and also for the allograft
rejection. It is becoming increasingly clear that
lymphocytes and macrophages, as primary effectors
of cellular and humoral immune responses, are the
focal points for many of the clinically useful
properties of glucocorticoids.
Recent evidence indicates that there is a
considerable inter-relationship between the immune
and neuroendocrine systems.
1-7 A number of
classical hormones, including steroids, peptides and
proteins, are able to exert a wide variety of effects
on immune responses, and receptors for these
hormones are located on the lymphocytes. In turn,
factors released from the immunocytes may
influence endocrine systems.
>7 Therefore, it may
well be hypothesized that there may exist an
immunoregulatory negative feedback circuit be-
tween immune and neuroendocrine systems. It has
been shown that glucocorticoid inhibited the
production of interleukin activity as measured by
bioassay, in rats and mice. However, striking
differences in susceptibility to glucocorticoids
(C) 1992 Rapid Communications of Oxford Ltd.
among species exist. Steroid-sensitive species
including the mouse, rat, rabbit and hamster,
experience dramatic lymphoid depletion after the
treatment. In contrast, guinea-pig, monkey and
human lymphocytes are resistant to the lytic eects
of glucocorticoids.
-1 Furthermore, the bioassay is
known to be influenced by other lymphokines and
monokines, and also the carry-over of glucocorti-
coids from the original cultures could influence the
bioassay.
Therefore, we investigated the effect of gluco-
corticoid on IL-6 production in human peripheral
blood mononuclear cells using a newly developed
specific radioimmunoassay system for IL-6.
Materials and Methods
Subjects: Normal subjects drawn from hospital
volunteers (six male, four female: age range 23-56
years) were studied. No subjects were on
medication or had any evident diseases.
Materials: Recombinant human IL-6 was purchased
from Genzyme, Cambridge, MA, USA. Lipopoly-
saccharide (LPS s. typhosa 0901) and Concanavalin
A (Con A) were obtained from Difco Laboratories,
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Detroit, MI, USA. Ph-ytohemagglutinin (PHA) was
purchased from GIBCO, New York, USA. Various
hormones, peptides, lectins, cytokines and growth
factors were obtained from the Protein Research
Foundation, Osaka, Japan. 12SI-recombinant IL-6
(specific activity: 5660 KBq//g) was obtained from
Amersham, England. Other substances were
purchased from Sigma, USA.
Immunization: Anti-recombinant human IL-6 anti-
bodies were generated in our laboratories as
previously reported in a method for IL-2
antibody1. Two New Zealand white rabbits were
immunized with 10 #g of IL-6 in 1.0ml water
emulsion in complete Freund’s adjuvant using
multiple subcutaneous injections at intervals of 4
weeks after each injection. The presence of
anti-IL-6 was checked.
Radioimmunoassay: All assays were performed in
duplicate in 12 x 75 mm polystyrene tubes. Dupli-
cate 100/1 volumes of samples or standards were
used and results were expressed as ng/ml of the
original samples. For the assay, 0.01 M phosphate
bul:fer (pH 7.4) with 0.15 M NaC1 and 0.2% BSA
was used. A double antibody radioimmunoassay
was performed utilizing goat anti-rabbit gamma-
globulin. A schematic diagram of the methodology
was shown in Table 1.
Culture of human peripheral blood mononuclear cells: Blood
from ten normal human subjects was separated on
Ficoll-Hypaque and peripheral blood mononuclear
cells (PBMC) were suspended in serum-free
medium (Nihon Seiyaku Co., Japan) composed of
various amino acids with insulin 2 mg/1, transferrin
2 mg/1, ethanolamine 0.122 mg/1, selenite 0.00914
mg/1 being added 100 #g/ml streptomycin, 100
U/ml penicillin, 0.01 M HEPES buffer (GIBCO,
USA) which had been passed through a ultra-
milipore filter. The cell concentration was 1 x 106
Table 1. A schematic diagram of the
assay procedure for L-6
standard or samples 0.1 ml
antibody (1 "800) 0.1 ml
1251-1L6 0.1 ml
buffer 0.5 ml
incubated for 24 h at 4C
added second antibody solution 0.1 ml
incubated for 24 h at 4C
cnetrifuged at 3000 rpm at 4C
decanted supernatants
counted (precipitants)
calculated bound/total count (B/T)
cells/ml. Five hundred #1 of the cell suspension was
added to flat bottom microtiter wells (NUNC,
Denmark) and 50/1 of either control medium or
medium containing various substances (10 #g/ml of
LPS and/or varying concentrations of hydro-
cortisone ranging from 10-M to 10
-3 M) were
added. After indicated hours of incubation at an
atmosphere of 5% CO2-95% air in a humidified
tissue culture incubator at 37C, at the end of 24,
48, 72 and 96 h, triplicate cultures were terminated
by centrifugation and collection of supernatant
fluids. Cell viability as assessed by trypan blue
exclusion was always greater than 96%. And
hydrocortisone itself did not affect the viability.
Column chromatography: Culture supernatant medium
containing high IL-6 concentration was obtained by
stimulating human peripheral blood cells and
chromatographed on a Sephadex G-50 (1 60 cm)
Table 2. Relative reactivity of cytokines, growth factors,
hormones, peptides and lectins in L-6 radioimmunoassay
relative reactivity*
human recombinant L-6
human recombinant L-I
human recombinant L-lfl
human recombinant L-2
human recombinant L-3
human recombinant L-4
human recombinant L-5
Interferon fl
TNF
NGF
Insulin
TRH
LHRH
Somatostatin
GHRH
CRH
TSH
LH
FSH
ACTH
Prolactin
fl-endorphin
fl-casomorphin
Leucine-enkephalin
Methionine-enkephalin
Dynorphin 1-13
Naloxone
VIP
Substance P
CCK-8
Tuftsin
Triiodothyronine
Thyroxine
LPS
IgG sorb
PHA
Con A
PWM
Staphylococcus aureus Cowan
Histamine
Serotonin
Dopamine
100
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
Arbitrary values of human recombinant L-6 100
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and eluted with 0.01 M phosphate buffer (pH 7.4)
collecting 1.0 ml fractions. The column was
calibrated with protein molecular weight markers.
Human recombinant IL-6 dissolved in culture
medium was similarly chromatographed. The
recovery of IL-6 from the column was evaluated by
addition of 12sI-IL-6 and was found to be
approximately 60%.
Recovery study: The known amounts of IL-6 were
added to the culture medium. The samples were
incubated at room temperature for 1 h before being
assayed in the IL-6 radioimmunoassay.
Statistics: Mean and standard deviation of the mean
were calculated. Student’s t-test was used to
evaluate the differences and it was considered
significant when p < 0.05.
Results
Generation of antibodies to IL-6 Both rabbits responded
to the immunization developing antibodies to IL-6
at a final titer of 1:2 000 or higher. An antiserum
used in this study was obtained 1 week after the
fourth injection. This serum showed a specific
binding at a final dilution of 1:16 000.
Specificity of antiserum: The specificity of anti-IL-6 is
shown in Table 2. No crossreactivity was observed
with cytokines, growth factors, various hormones,
peptides and lectins (Table 2).
Binding of 125I-IL-6 to anti-IL-6: A comparison of the
binding inhibition curves obtained from a series of
three experiments when the known concentrations
of IL-6 are diluted in either assay buffer or culture
medium is shown in Fig. 1. The binding inhibition
curves were virtually superimposable when 125I-
recombinant IL-6 (Amersham, England) was used.
The dilution curve drawn by culture supernatant
FIG. 1. Standard curves for the IL-6 radioimmunoassay with 11_-6
standards diluted in buffer or culture medium (O--O) incubated with
1251-recombinant IL-6 and dilution curve by supernatant medium with
high 11_-6 concentration produced by stimulating human peripheral blood
mononuclear cells ([]--I).
IL6
ng/ml
2.
culture supernatant
containing high IL6
hilL6
10 14 18 22 26 30 34
Fraction Number
FIG. 2. Elution profile of authentic human recombinant IL-6 (.) and
immunoreactive IL-6 produced by human peripheral blood mononuclear
cells (VI) on Sephadex G-50.
medium containing high IL-6 level produced by
PBMC was parallel with the standard curve (Fig. 1).
50pg/ml of IL-6 was consistently detected in
this assay system. Intra-assay and inter-assay
variations were 6.9% and 7.2%, respectively, when
assayed by eight identical samples.
Column chromatography" As depicted in Fig. 2, culture
supernatant medium with a high IL-6 concentration
produced by PBMC on Sephadex G-50 showed one
IL6
ng/ml
LPS
IgG
o----O PHA
ConA
day of culture
FIG. 3. Kinetics of IL-6 production. The Fig. shows IL-6 concentration
measurable in supernatants of cultured human peripheral blood
mononuclear cells. Each point represents mean-I-SD of IL-6 level of
supernatants in ng/ml, plotted on vertical axis (n 10). Closed circles,
squares, open circles and crosses represent LPS-, IgG-, PHA- and Con
A-stimulated PBMC, respectively.
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peak of immunoreactive material which corre-
sponded to IL-6 (Fig. 2).
Recovery of IL-6 added to medium" There is a nearly
complete recovery of IL-6 when added to medium
(data not shown).
Kinetics of IL-6 production" Human PBMC from ten
healthy normal subjects were set up in culture in
microtitre plate. Cultures were initiated with or
without LPS (10 #g/ml). IgG SORB(IgG, 0.1%),
PHA (30/g/ml) and Con a(100#g/ml). At
indicated times after the initiation (day 1, 2, 3 and
4) control and LPS-, IgG-, PHA- or Con
A-stimulated cultures were terminated, the super-
natants separated by centrifugation and assayed for
IL-6, as shown in Fig. 3. The experiment was done
three times and the results obtained were almost the
same. Therefore the typical result was shown in Fig.
3. It was observed that detectable and peak levels
of IL-6 were present in the LPS-, IgG-, PHA- and
Con A-stimulated cultures after 24 h (mean + SD;
2.71 q- 0.85 ng/ml, 1.99 -+- 0.87 ng/ml, 2.06 _-q- 1.00
ng/ml and 1.50 _+ 0.88 ng/ml, respectively) and
then declined. The responses shown in Fig. 3 were
maximal for each of the reagents tested. IL-6 levels
were not detectable at any time in the supernatants
of the corresponding eight unstimulated control
cultures.
Effect of hydrocortisone on IL-6 production: Hydro-
cortisone alone did not raise IL-6 production at any
of the concentrations tested. PBMCs were stimu-
lated with LPS and cultured in the presence of
hydrocortisone (10-1 M to 10 -3 M). IL-6 produc-
tion by LPS-stimulated PBMC was found to be
dramatically sensitive to the presence of hydro-
cortisone. As shown in Fig. 4, a dose-dependent
hydrocortisone-induced inhibition of IL-6 produc-
tion was observed. However, there was a wide
variation in the response to hydrocortisone, with
three distinct populations being identified. Based on
the concentration required to inhibit 50% of LPS-
stimulated IL-6 production, three of ten subjects
were at 10
-6 M, three at 10 -s M and the remaining
four at 10-4M (Fig. 4). At the concentra-
tion of 10-3 M, there was almost complete
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FIG. 4. Effects of varying concentrations of hydrocortisone ranging from 10-1 M to 10-3 M on IL-6 production stimulated by LPS (10 #g/ml) in ten
normal human peripheral blood mononuclear cells. Each symbol represents an individual subject. SD of triplicate cultures was omitted to avoid further
complication of the Fig. Without exception, the SD obtained at any cases was never greater than 8.7%. Results expressed as per cent decrease of
the incubation without hydrocortisone.
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inhibition of IL-6 production, whereas 10-M
hydrocortisone produced IL-6 equal to that induced
by LPS alone. The experiment was carried out on
blood from the same individual three times and the
results were almost the same.
Discussion
We have developed a radioimmunoassay for
human IL-6 with a sensitivity to 50 pg/ml. The
assay utilized iodinated human recombinant IL-6
and rabbit antisera raised against IL-6. The assay
detects IL-6 in the presence of mitogens or
substances that might interfere with bioassay
systems for IL-6. The specificity, reproducibility
and usefulness have been demonstrated.
The immunosuppressive effect of glucocorticoid
in vivo and in vitro is well documented and
glucocorticoid is widely used in a variety of diseases
for it. Today, increasing evidence suggest that there
exists bidirectional communication between the
immune and neuroendocrine systems. In the present
study, we observed that hydrocortisone inhibited
LPS-stimulated IL-6 production in a dose-de-
pendent manner. Given the key role of IL-6 in
enhancing lymphocyte function, hydrocortisone
inhibition of IL-6 is likely to be an important
immunosuppressive effect of this drug in vivo. It was
also observed that there was a wide variation in the
responsiveness to hydrocortisone in terms of the
concentrations required to inhibit 50% of the
LPS-stimulated IL-6 production. There was no
discernable relationship between the inhibitory
effect of hydrocortisone and age or sex in the
present study. Some investigators suggested that
activated lymphocytes were insensitive to gluco-
corticoid inhibition. 8’9 Our results are in disagre-
ment with this, but, in agreement with the more
recent report that indicated that activated lympho-
cytes contain increased numbers of glucocorticoid
receptors and are sensitive to glucocorticoid-
induced metabolic inhibition.1 However, we
cultured human peripheral blood mononuclear cells
which contain not only lymphocytes but also
monocytes in terms of the source of IL-6
production. Therefore, the experiments may not
permit conclusions on the direct effects of
glucocorticoids only on lymphocyte function. The
varied inhibition of IL-6 production by glucocorti-
coid may partly explain the widely believed-notion
that the human is a steroid resistant species,
8
although the physiological relevance of the effects
is not clear because the effects were seen at
pharmacological doses. The present findings
suggested that a major mechanism of glucocorti-
coid-mediated immunosuppression may work at the
level of the IL-6 production. And the data also
suggested that to measure the glucocorticoid-
sensitivity to IL-6 production in vitro might provide
an indicator for the efficacy of the immunosup-
pressive therapy of steriods in vivo.
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